Daniel R. Karlin, MD, MA

Early phase 3 results show that a single dose of MM120 can rapidly reduce anxiety symptoms in GAD patients, with effects lasting up to 12 weeks.

With an FDA Breakthrough Therapy Designation, what are the next steps for MM-120?

MindMed has announced the first patient has been dosed in its phase 3 study Panorama.

With MM120 in phase 3 in the MindMed trial, what place do psychedelics hold in psychiatry?

MindMed announced phase 3 study of psychedelic MM120 for Generalized Anxiety Disorder.

According to the chief medical officer of MindMed, it is time to look past the history of LSD.

Generalized anxiety disorder: has it been sidelined by MDD? MM-120 is a new treatment under investigation for this disorder, making waves.